Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
ACLX

ACLX - Arcellx, Inc. Stock Price, Fair Value and News

$68.08-0.43 (-0.63%)
Market Closed

8/100

ACLX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

8/100

ACLX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$54.16

Target 3M

$60.93

Target 6M

$57.55

ACLX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ACLX Price Action

Last 7 days

-1.1%

Last 30 days

4.5%

Last 90 days

-22.2%

Trailing 12 Months

6.0%

ACLX RSI Chart

ACLX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ACLX Valuation

Market Cap

3.9B

Price/Earnings (Trailing)

-18.07

Price/Sales (Trailing)

109.66

EV/EBITDA

-18.41

Price/Free Cashflow

-19.57

ACLX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$54.16

Target 3M

$60.93

Target 6M

$57.55

ACLX Fundamentals

ACLX Revenue

Revenue (TTM)

35.9M

Rev. Growth (Yr)

-80.99%

Rev. Growth (Qtr)

-34.49%

ACLX Earnings

Earnings (TTM)

-217.9M

Earnings Growth (Yr)

-115.65%

Earnings Growth (Qtr)

-5.7%

ACLX Profitability

EBT Margin

-602.73%

Return on Equity

-49.44%

Return on Assets

-33.22%

Free Cashflow Yield

-5.11%

ACLX Investor Care

Shares Dilution (1Y)

6.93%

Diluted EPS (TTM)

-3.93

ACLX Alerts

  • 2 major insider sales recently.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202576.8M57.0M35.9M0
2024131.7M144.7M155.8M107.9M
2023000110.3M
Get all data in R, Python etc through our Historical Stock Data APIs

About Arcellx, Inc.

ACLX
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and product candidates for solid tumor programs. It has strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize CART-ddBCMA. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.
 CEO
 WEBSITEhttps://arcellx.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES98

Arcellx, Inc. Frequently Asked Questions

ACLX is the stock ticker symbol of Arcellx, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Arcellx, Inc. is 3.94 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check ACLX's fair value in chart for subscribers.

The fair value guage provides a quick view whether ACLX is over valued or under valued. Whether Arcellx, Inc. is cheap or expensive depends on the assumptions which impact Arcellx, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ACLX.

As of Wed Jan 28 2026, ACLX's PE ratio (Price to Earnings) is -18.07 and Price to Sales (PS) ratio is 109.66. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ACLX PE ratio will change depending on the future growth rate expectations of investors.